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Background: Ameloblastic fibrosarcoma (AFS) is a rare odontogenic neoplasm of the jaw that usually arises de novo or through
a malignant change in the mesenchymal component of a preexisting or recurrent benign fibroma. The majority of AFS cases
reported in the literature arise in the mandible.
Case Report: A 35-year-old male presented with an asymptomatic left maxillary mass that on imaging was found to be effacing
most of his maxillary sinus. He underwent a left maxillectomy with free-flap reconstruction and adjuvant radiotherapy to the
tumor bed.
Conclusion: Wide local excision remains the treatment of choice for AFS, given the poor survival rates of patients with recurrent
disease. However, long-term studies and follow-up are needed to elucidate the role of adjuvant therapies in the primary
treatment of AFS.
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INTRODUCTION
Ameloblastic fibrosarcoma (AFS) is a rare odontogenic
neoplasm characterized by marked cytologic atypia, in-
creased cellularity with diminution of the epithelial compo-
nent, and aggressive behavior. Approximately 60 cases of
AFS have been reported in the literature to date, with most
cases located in the mandible.1 This low-grade sarcoma also
has a slightly male preponderance with a mean age of 27.3
years.2 The main symptoms during presentation are pain,
swelling, and rapid growth. If inadequately treated, AFSs
show a high rate of local recurrence, but distant metastasis
is extremely rare. The optimal treatment for patients with this
type of sarcoma is usually wide surgical excision and long-
term follow-up.3 The value of adjuvant treatment with
chemotherapy or radiation therapy remains uncertain, and
adjuvant therapy is generally only used in patients with
multiple episodes of recurrence after initial resection.4
CASE REPORT
A 35-year-old male presented with an asymptomatic left
maxillary mass extending into the sinus cavity. He had
initially presented to his dentist with a swelling in the upper
left buccal sulcus. Radiographic examination consisting of
an orthopantomogram (OPG) showed bony destruction of
the left maxilla (Figure 1). The OPG findings were initially
thought to represent an abscess or cyst, and the patient
was referred to an oral and maxillofacial surgeon for further
management. A prebiopsy computed tomography (CT)
scan showed an expansile lesion in the left maxilla effacing
most of the maxillary sinus. The maxillofacial surgeon
removed most of the mass and sent the tissue for
histology. AFS in the left maxilla was diagnosed based
on the histopathology. The histologic pattern of AFS
superficially resembles ameloblastic fibroma with nests
and cords of odontogenic epithelium set in a connective
tissue background. The epithelial tissue was benign
(Figure 2A), but the connective tissue component was
malignant with hypercellularity of the mesenchymal com-
ponents, some variability in nuclear size and shape, and
obvious mitotic activity (Figure 2B). Chest CT and positron
emission tomography scans showed no evidence of
metastatic neoplastic disease.
The patient subsequently underwent a left maxillectomy
with reconstruction with a left deep circumflex iliac artery
bone free flap, using the iliac crest to reconstruct the parts
of the maxilla that were resected. A composite free flap was
chosen because of the extent of the resection that included
the whole maxilla and the orbital floor on the left side. In
addition, a bony reconstruction allows the future placement
of dental implants. Histology of the resected maxilla showed
a biphasic neoplasm with a prominent stromal component
and a less prominent epithelial component. Whether the
hypocellular areas without atypia or mitotic activity repre-
sented heterogeneity within the stroma or a preexisting
benign lesion is uncertain. Although the tumor appeared to
be completely removed, radiotherapy was recommended
because of the proximity of the margin. Accordingly, 63 Gy
in 35 fractions was administered to the tumor bed.
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CASE REPORT
DISCUSSION
AFS is a rare odontogenic neoplasm derived from the
ectomesenchyme of the dental pulp. In our case, the AFS
arose within the maxilla, a considerably rare occurrence, as a
majority of reported cases have been located in the molar
and premolar regions of the mandible.3 While our case most
likely arose de novo, a number of cases have been reported
in which AFS arose from a preexisting ameloblastic fibroma.2
Radiologic features that are suggestive of possible lytic
tumors are usually not diagnostic, as in our case, in which
the initial findings on the OPG were thought to represent a
cyst or abscess. The diagnosis was made from the
histologic features that distinguish AFS from other sarco-
mas, fibromas, and blastomas of the maxillofacial region.
A wide surgical excision with clear margins seems to be
the most reliable and significant prognostic factor for a
favorable survival rate. Wide excision and clear margins are
especially important because the survival rate in patients
with local recurrence is poor.5
Adjuvant therapy in the treatment of AFS has generally been
reserved for patients who have unresectable disease or need
salvage operations following the initial surgery. High-dose
radiation therapy to the tumor bed may help reduce the
recurrence rate and local extension of the tumor.6 However,
the decision to administer radiation therapy in a young patient
is a balance between reducing the risk of local recurrence vs
increasing the chances of a secondary malignancy years later.
To our knowledge, only 1 case of chemotherapy used to
treat a patient with ameloblastic fibroma that underwent
transformation to an ameloblastic fibrosarcoma during
recurrence has been reported.4 Actinomycin D, vincristine,
and cyclophosphamide were the chemotherapeutic agents
used to produce a 50% reduction in the tumor mass.
However, the clinical course was complicated by metastatic
melanoma that resulted in the patient’s death.
CONCLUSION
Definitive treatment of this disease remains difficult to define
because of limited data and long-term follow-up of patients
with this rare sarcomatous neoplasm. Surgical resection
remains the standard treatment, as no clear or consistent
pattern exists for the use of adjuvant therapy in the primary
Figure 1. Preoperative orthopantomogram shows cortical thinning and bony destruction of
the left side of the alveolar process of the maxilla.
Figure 2. A: Islands of ameloblastic epithelium set in a connective tissue background. The
overall pattern is ameloblastic fibroma–like, but some of the background is more cellular than
would normally be expected in a benign lesion. B: Small ameloblastic strands set in amarkedly
hypercellular background with some mitotically active cells.
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treatment of AFS. However, in this case, early and aggressive
treatment of this cancer with both surgery and adjuvant
radiotherapy was considered the best treatment modality.
Our patient will need ongoing close and long-term follow-up.
We hope this treatment will be sufficient to prevent recurrence
and give our patient the best chance of long-term survival.
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